Adaptogens Explained: Ashwagandha, Rhodiola, and the Stress Response

The term "adaptogen" was coined in 1947 by Soviet pharmacologist Nikolai Lazarev and developed further by Israel Brekhman in the 1960s to describe a class of compounds that non-specifically increase resistance to biological stress. The concept arose from Soviet military research into performance enhancement under extreme conditions. Decades later, the term has been adopted wholesale by the wellness industry as marketing language for a diverse range of botanical supplements, most of which don't meet the original pharmacological criteria and many of which lack meaningful clinical evidence.

Within this category, two compounds stand out as having genuine mechanistic rationale and the most robust human clinical evidence: ashwagandha (Withania somnifera) and Rhodiola rosea. Understanding what these plants actually do requires understanding the biology of stress they target — the HPA axis.

The HPA Axis and Why Adaptogens Target It

The hypothalamic-pituitary-adrenal (HPA) axis is the body's primary hormonal stress response system. When the brain perceives a stressor, the hypothalamus releases corticotropin-releasing hormone (CRH), which signals the pituitary to release ACTH, which signals the adrenal glands to produce cortisol. Cortisol mobilizes energy, suppresses immune function and inflammation, and prepares the body for immediate demands. This acute response is adaptive and life-sustaining.

Chronic stress, however, produces persistent HPA activation, sustained elevated cortisol, progressive HPA dysregulation, and downstream effects including impaired sleep, anxiety, impaired memory and concentration, suppressed immune function, disrupted sex hormone production, and elevated cardiovascular risk. Adaptogens, at least the well-studied ones, appear to work primarily by modulating HPA axis reactivity — reducing cortisol output under stress conditions, improving HPA negative feedback, and supporting the recovery phase after acute stress.

Ashwagandha: The HPA Modulator

Ashwagandha's primary active compounds are withanolides, steroidal lactones that modulate stress response pathways. Multiple RCTs using standardized extracts (KSM-66 or Sensoril) have found consistent reductions in serum cortisol (14–28% below baseline in controlled studies), reduced PSS (Perceived Stress Scale) scores, and improvements in GAD-7 anxiety scores in clinically stressed populations. The signal for stress and anxiety is the most replicated and credible finding in the adaptogen literature.

Important context: the benefits are most pronounced in individuals with elevated baseline stress and cortisol — the effect appears to be normalizing rather than uniformly cortisol-suppressing. In healthy, unstressed individuals, ashwagandha's effects are considerably more modest. This is actually consistent with the original adaptogen concept of non-specific stress resistance rather than pharmacological suppression of a normal physiological response.

The safety caveat: a growing number of case reports of ashwagandha-associated hepatotoxicity in susceptible individuals has emerged. The mechanism is likely immune-mediated rather than directly toxic, and cases primarily involve higher doses (>500 mg/day) and non-standardized products. Cycling — 8–12 weeks on, 4 weeks off — is the standard recommendation to minimize prolonged exposure risk.

Rhodiola Rosea: The Fatigue and Burnout Adaptogen

Rhodiola rosea is a root used in traditional medicine across Scandinavia, Russia, and Central Asia for centuries, particularly for fatigue, cold weather performance, and mental endurance. Its primary active compounds are rosavins and salidroside, which appear to modulate catecholamine release (dopamine, norepinephrine, serotonin) in addition to HPA axis effects, providing a somewhat different neurochemical profile from ashwagandha.

The clinical evidence for Rhodiola is strongest for burnout and fatigue-related conditions. A 2009 RCT by Olsson et al. (Planta Medica 75(2):105–112, PMID 19016404) randomized 60 adults with stress-related fatigue to standardized Rhodiola rosea extract SHR-5 (576 mg/day) or placebo for 28 days. The Rhodiola group showed significant improvements in fatigue (Pines Burnout Scale), attention (concentration test), and morning salivary cortisol response — with particularly notable improvements in cognitive function and mental fatigue measures. A 2012 systematic review by Hung et al. in Phytomedicine concluded Rhodiola shows a signal for physical and mental fatigue under stress conditions but noted variable trial quality.

For acute cognitive performance under stress (exam pressure, shift work, sleep deprivation), Rhodiola has a reasonably consistent evidence base across several trials. The effect is more stimulant-like in onset than ashwagandha's more gradual HPA modulation — some users describe a faster-onset sense of mental clarity and reduced fatigue. This appears related to salidroside's effects on monoamine neurotransmitter systems.

Why Cycling Matters

The cycling recommendation for adaptogens is not an arbitrary convention — it reflects genuine uncertainty about long-term HPA axis effects. The HPA axis has elaborate negative feedback mechanisms that prevent chronic cortisol oversuppression. Chronically blunting cortisol responses through prolonged adaptogen use may theoretically alter HPA sensitivity and feedback set points. There is limited human data on adaptogen effects with continuous use beyond 12–16 weeks. The practical protocol most herbalists and researchers recommend is: 8–12 weeks of active use, 2–4 weeks off, repeat as needed. This approach minimizes unknown long-term risks while preserving the short-term benefits in high-stress periods.